Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
JX10, Jx10 placebo drug product is prepared as a sterile, lyophilized white to light yellow cake or powder for infusion.
Pharma Mar S.A.
Acute ischemic stroke
1 trial -
JZP258
Pharma Mar S.A.
Narcolepsy
1 trial -
KEYTRUDA 25 mg/mL concentrate for solution for infusion, LIBTAYO 350 mg concentrate for solution for infusion., Placebo for Fianlimab, Fianlimab
Pharma Mar S.A.
Melanoma
1 trial -
KVD900, KVD900
Pharma Mar S.A.
Hereditary Angioedema Type I or II
1 trial -
KVD900, KVD900
Pharma Mar S.A.
Hereditary Angioedema Type I or II
1 trial -
Kreon 35 000 Ph. Eur. Lipase Einheiten, magensaftresistente Hartkapseln
Pharma Mar S.A.
Male and female patients aged ≥ 18 to ≤ 85 years with a total pancreatectomy with Pancreatic Exocrine Insufficiency (PEI).
1 trial -
LANSOPRAZOLE, LANSOPRAZOLE, Placebo to match lansoprazole high dose, Linaprazan glurate, Placebo to match Lansoprazole low dose, Placebo to match Linaprazan Glurate
Pharma Mar S.A.
Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)
1 trial -
LIBTAYO 350 mg concentrate for solution for infusion., Armisarte 25 mg/ml concentrate for solution for infusion, Gemcitabine 2 g Powder for Solution for Infusion, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion
Pharma Mar S.A.
Non-small Cell Lung Cancer
1 trial -
LIBTAYO 350 mg concentrate for solution for infusion., matching Placebo with R2810
Pharma Mar S.A.
Cutaneous Squamous Cell Carcinoma (CSCC)
1 trial -
LOMUSTINE, 4-L-[131I]iodo-phenylalanine, LOMUSTINE
Pharma Mar S.A.
Glioblastoma
1 trial -
LP352 (bexicaserin) Placebo Oral Solution, Bexicaserin
Pharma Mar S.A.
Developmental and Epileptic Encephalopathies (DEE)
1 trial -
LP352 (bexicaserin) Placebo Oral Solution, Bexicaserin
Pharma Mar S.A.
Developmental and Epileptic Encephalopathies (DEEs)
1 trial -
Locally sourced sterile 0.9% (w/v) sodium chloride, JEMPERLI 500 mg concentrate for solution for infusion
GlaxoSmithKline Biologicals S.A.
Neoplasms, Head and Neck
1 trial -
Lucerastat
Pharma Mar S.A.
Fabry disease
1 trial -
MEPOLIZUMAB
GlaxoSmithKline Biologicals S.A.
Hypereosinophilic syndrome (HES)
1 trial -
METHOTREXATE, DEXAMETHASONE, DEXAMETHASONE, CYTARABINE, CYTARABINE, DASATINIB, PREDNISOLONE, CYTARABINE, PONATINIB, CYTARABINE, METHOTREXATE, METHOTREXATE, VINCRISTINE SULFATE, PREDNISOLONE, IMATINIB MESILATE, METHOTREXATE, DEXAMETHASONE, Olverembatinib, DEXAMETHASONE, VINCRISTINE SULFATE, DEXAMETHASONE, DASATINIB, DEXAMETHASONE
Pharma Mar S.A.
Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
1 trial -
MIDAZOLAM , PROPOFOL , ROCURONIUM BROMIDE , Cipepofol Injectable Emulsion, FENTANYL , SEVOFLURANE , PROPOFOL
Pharma Mar S.A.
General anaesthesia
1 trial -
MITAPIVAT, MITAPIVAT, "Placebo to Match Mitapivat Tablets, 5 mg and 20 mg, are supplied as film-coated, blue, round tablets for oral administration Placebo to Match Mitapivat Tablets, 50 mg or 100 mg, are supplied as film-coated, blue, oblong tablets for oral administration. Placebo to Match Mitapivat Granules, 1 mg, are supplied as film-coated, white, round granules for oral administration", MITAPIVAT
Pharma Mar S.A.
Anemia in subjects with sickle cell disease (SCD)
1 trial -
MITAPIVAT, MITAPIVAT, Placebo for AG-348, MITAPIVAT, MITAPIVAT
Pharma Mar S.A.
Pyruvate Kinase Deficiency
1 trial -
MITAPIVAT, Placebo for MITAPIVAT, MITAPIVAT, MITAPIVAT, MITAPIVAT
Pharma Mar S.A.
Pyruvate Kinase Deficiency
1 trial -
MITAPIVAT, Placebo for Mitapivat
Pharma Mar S.A.
Transfusion-Dependent Alpha- or Beta-Thalassemia
1 trial -
MT-7117 Formulation Code C
Pharma Mar S.A.
Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
1 trial -
MT-7117 Formulation Code C, MT-7117 Placebo
Pharma Mar S.A.
Erythropoietic Protoporphyria or X-Linked Protoporphyria
1 trial -
MaaT013
Pharma Mar S.A.
Treatment of acute graft-versus host disease (aGvHD) to the gastrointestinal (GI) tract of patients who are resistant or intolerant to ruxolitinib.
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources